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Objective: To determine treatment patterns and costs over a two-year period among new 
initiators of topical prostaglandin analogs in a managed care population by retrospective cohort 
analysis of an insurance claims database.
Methods: Patients who initiated therapy with a prostaglandin analog between September 2006 
and March 2007 were identified. The use of monotherapy and adjunctive therapies were compared 
by index prostaglandin. Days to initiation of adjunctive therapy and rates of   glaucoma surgical 
procedures were also calculated. Medical costs (antiglaucoma medications and ophthalmic 
visits) over the two-year period were estimated.
Results: The analysis identified 5018 patients with at least one prostaglandin analog 
  prescription (bimatoprost, n = 747; latanoprost, n = 1651; benzalkonium chloride (BAK)-free 
  travoprost, n = 203). The majority (51%–54%) had repeat prescriptions. Among those with 
repeat   prescriptions, 52% were female (not significant) and mean age was 64 years (P , 0.01). 
Rates of adjunctive therapy use varied across groups (bimatoprost 51%, latanoprost 37%, and 
  BAK-free travoprost 35%, P , 0.0001). Median and mean days to initiation of adjunctive therapy 
were 83 and 140 for bimatoprost, 101 and 181 for latanoprost, and 113 and 221 for   BAK-free 
  travoprost. Two-year medical costs were $3147, $2843, and $2557 for patients initiating 
  treatment with bimatoprost, latanoprost, and BAK-free travoprost, respectively. Use of glaucoma 
surgical procedures across the treatment groups was similar over the two-year period.
Conclusions: Over a two-year period, the rate and time to initiation of adjunctive therapy use, 
as well as medical costs, varied between index prostaglandins. However, the rate of glaucoma 
surgical interventions did not vary significantly across index medications.
Keywords: costs and cost analysis, drug therapy, combination, glaucoma, prostaglandin analogs
Introduction
Patient adherence to glaucoma treatment regimens is essential to maintain maximum 
intraocular pressure (IOP) reduction and to delay disease progression in patients with 
primary open-angle glaucoma.1 However, adherence with glaucoma treatment is a 
known problem, with multiple studies suggesting that more than half of glaucoma 
patients who initiate treatment fail to refill prescriptions.2–6 Reasons for   nonadherence 
can vary, ranging from patient characteristics, such as race, travel, or financial 
  challenges, to poor patient-doctor communication, limited understanding of the risks 
of nonadherence, or not being willing to discuss adverse events with the physician.7 
Some of these reasons are common across medications and medication classes, but 
adverse events is one area in which differences between medications may have an impact 
on patient adherence and treatment efficacy. For example, recent estimates suggest 
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patients.8 Limiting the use in IOP-lowering   medications of 
the preservative benzalkonium chloride (BAK), which is 
associated with increased rates of OSD,8,9 may minimize 
these rates.
Minimizing preservatives such as BAK can be accom-
plished in a number of ways and can have important long-
term eye health benefits. Using a BAK-free product and 
limiting exposure by prescribing monotherapy instead of 
polypharmacy are ideal ways to do this, but monotherapy 
may not be sufficient to lower IOP adequately and   adjunctive 
therapies are required. The introduction of adjunctive 
therapies multiplies negative influences on adherence (ie, 
complexity of regimen, likelihood of adverse events)10,11 
and increases exposure to BAK which has been linked to 
decreased success with filtration surgery.12 Therefore, the 
simplest treatment regimen, with lowest exposure to BAK 
and the least need for adjunctive therapy, is optimal. Not 
only does increased medication complexity decrease adher-
ence,10,13 but adverse events such as OSD associated with 
BAK can affect adherence.7
In theory, these recommendations seem reasonable, but 
only a real-world comparison of treatments can address the 
issue adequately. Several studies with one-year follow-up 
of patients treated with a BAK-free prostaglandin   analog 
(  BAK-free travoprost) compared with those treated with alter-
native prostaglandin analogs (bimatoprost and   latanoprost) 
have been published.4–6 Each study used the same inclusion 
criteria and identified patients with a prescription for a topical 
prostaglandin analog during a six-month period and who had 
no glaucoma therapy claims in the six months prior and had at 
least 12 months of data available after the initial prostaglan-
din analog claim. These studies have consistently found that 
during the first year of treatment, a BAK-free prostaglandin 
analog was associated with lower rates of adjunctive therapy, 
a longer time until initiating adjunctive therapy, and lower 
first-year costs.
While these studies present evidence that BAK-free 
  travoprost provides treatment advantages within a single year 
of follow-up, it was useful to extend this analysis to include 
two years and to examine glaucoma surgical   procedures 
as a possible confounder of previous study findings, ie, 
whether surgical procedures were performed at different 
rates across groups and thus affected the need for further 
  pharmacotherapy. The goals of this study are similar to the 
previous analyses, ie, to evaluate the treatment patterns and 
costs of patients newly initiating therapy with prostaglandin 
analogs as first-line therapy. However, a different health 
care database was used, which included glaucoma surgical 
procedural data. Thus, this study includes an analysis of 
these findings, along with an evaluation of pharmaceutical 
treatment data over a two-year period.
Methods
The patients described in the retrospective cohort analysis 
were receiving prescription benefits and were included in 
the Integrated HealthCare Information Services National 
  Managed Care Benchmark Database, a medical claims 
database covering managed care plans that serve more than 
30 million members across the US. All data were deidentified 
in accordance with Protected Health Information standards 
under the Health Information Portability and Accountability 
Act, so that no individually identifiable information was 
included in the study database. Therefore, review by an 
institutional review board was not required.
The study cohort included patients who first initiated 
therapy with one of three prostaglandin analog products 
(bimatoprost, latanoprost, or BAK-free travoprost) between 
September 1, 2006 and March 30, 2007. To qualify, patients 
had to have at least one claim for primary open-angle 
glaucoma (International Classification of Diseases, Ninth 
Revision, Clinical Modification [ICD-9-CM] code 365.11) 
during the observation period and six months of prior claims 
data in which there were no glaucoma therapy claims of any 
class. The index date was defined as the first date on which 
a prostaglandin analog was filled. Glaucoma therapy claims 
were defined by National Drug Codes. The study population 
was further defined by requiring patients to have at least 
24 months of uninterrupted use of the index prostaglandin 
analog following the index date (initial prescription fill). 
This was operationalized as not having prescriptions for any 
other prostaglandin analogs during the follow-up period and 
having at least one prescription for the index   prostaglandin 
analog during months 19–24 of the follow-up period. 
Patients were required to be continuously enrolled, as per 
the   eligibility database, during the 30-month observation 
period (six months prior to the first prostaglandin claim and 
the 24 months of follow-up). Patients who did not meet these 
requirements (sufficient prior claims data, uninterrupted use, 
and repeat use of the index prostaglandin) were excluded 
from the study database. We considered that patients added 
an adjunctive medication, defined by National Drug Code, if 
there was a sequential and subsequent refill of an adjunctive 
agent in the presence of continued refills for the index agent. 
Adjunctive medications were described by type (  adrenergics, 
beta-blockers, carbonic anhydrase inhibitors, miotics, 
  prostaglandin analogs, fixed combinations, others).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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The analysis identified patients by the prostaglandin 
  prescription they first filled (ie, the “index medication”) 
during the study period, with one exception. Patients who 
initiated treatment with the original formulation of travoprost 
but then switched to the BAK-free formulation after a single 
prescription for the original formulation were included in the 
BAK-free cohort. Participants were characterized in terms 
of available demographic characteristics (age and gender). 
Gender was compared using a Chi-square test and age was 
compared using analysis of variance (ANOVA). The use 
of monotherapy and adjunctive therapies was compared. 
Median and mean number of days to initiation of adjunctive 
therapy were calculated for each cohort, with the distribution 
of number of days examined to determine which measure 
to use in the model. The median numbers of days until 
patients added adjunctive therapies were compared using a 
  Wilcoxon rank sum approach, and mean times were compared 
using ANOVA. The rate of selected surgical procedures for 
  glaucoma, as specified in the published literature,14,15 was 
calculated over the observation period, with rates compared 
across patient cohorts, controlling for age and gender. Statisti-
cal comparisons were conducted in SAS v9.2 (SAS Institute, 
Inc., Cary, NC).
The American Academy of Ophthalmology Preferred 
Practice Patterns for glaucoma suggest that follow-up care 
should be based on achievement of target IOP and the amount 
of disease progression,16 neither of which was available in the 
prescription database used for this study. Therefore, the base 
case analysis uses resource rates from a survey-based study17 
while sensitivity analyses explore visits, as recommended by 
other studies and guidelines.16,18 Because all patients in the 
model are assumed to undergo the same procedures and tests 
at their visits regardless of the prostaglandin analog they 
receive, the relatively small differences across studies in 
terms of the components of each visit have minimal impact 
on the study findings.
At the initial visit, patients are assumed to have a level 4 
(comprehensive) evaluation (Current Procedural Terminol-
ogy, 92004). Follow-up visits are assumed to be level 2 
(  intermediate) visits (Current Procedural Terminology 92012), 
with three follow-up visits during the first year (likely but not 
necessarily at 30 and 90 days following initiation of the index 
therapy and at 12 months, and then an additional two visits 
in the following year). Two additional follow-up visits are 
assumed to be associated with the initiation and   monitoring 
of adjunctive medication among patients for whom it is pre-
scribed. Thus, patients who stay on monotherapy are assumed 
to have one comprehensive visit and five   intermediate 
visits, while those who require adjunctive therapy had one 
  comprehensive visit and seven intermediate visits. Table 1 
presents the procedures and diagnostic tests that comprised 
each visit, as well as the costs used for each.
We used average wholesale price (AWP) for 2009 as the 
basis of prescription costs.19 The range of published AWPs 
for the prostaglandin analogs was fairly narrow ($80.53 to 
$82.67).19 For the prostaglandin analogs, the midpoint cost 
for the agents is used in the model because AWP is the best 
publicly available estimate for the analysis. Further, the num-
ber of prescriptions for prostaglandin analogs was expressed 
as 2.5 mL size bottle equivalents, because this is the most 
common size found in the claims database and represents 
approximately a 30–45 day supply when used as per label 
in both eyes. For example, a 5 mL bottle was treated as two 
2.5 mL bottles. The AWPs for adjunctive therapies were 
also reviewed in the Red Book.19 For the base case of the 
model, branded products were used, but sensitivity analyses 
explored lower costs. Days of use per bottle are based on 
data from previously published studies.4,5 Number of bottles 
required is rounded to the nearest tenth. Medical charges are 
estimated using the 75th percentile of physicians’ fees from 
a published benchmark.20 All the costs used in the model are 
presented in Table 2.
Results
A total of 5018 patients were identified who had six months 
of glaucoma-free eligibility and 24 months of   continuous 
eligibility after an initial prescription for bimatoprost, 
latanoprost, or BAK-free travoprost (Figure 1). Of the 1382 
bimatoprost patients, 747 had repeat prescriptions, and of 
the 3247   latanoprost patients, 1651 had repeat prescriptions. 
Among the 389 patients who initiated with BAK-free travo-
prost, 203 had repeat prescriptions (ie, no other prostaglan-
dins during the follow-up period plus at least one repeat of 
the index   prescription in months 19–24). Fifty-six of these 
203 had an initial prescription with the original formulation 
of travoprost and were then transitioned to the BAK-free 
formulation. Persistence patterns differed only slightly across 
groups, with 54% of bimatoprost patients remaining on the 
Table 1 Demographic characteristics
Characteristic BAK-free 
travoprost
Bimatoprost Latanoprost
n 203 747 1651
Age, mean ± SD* 62.1 ± 10.7 65.1 ± 10.7 64.1 ± 11.5
gender, % female 50.7% 49.4% 53.4%
Note: *P = 0.0096 across treatment groups.
Abbreviations: BAK, benzalkonium chloride; SD, standard deviation.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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index therapy, while 51% of latanoprost patients and 52% of 
BAK-free   travoprost patients remained on the index therapy. 
Figure 1 details the patient population persistence patterns.
Demographic characteristics by index medication are pre-
sented in Table 1. Average age across all groups was 64 years, 
and 52% of the patients were female. Gender was similar 
across groups, although there were significant differences in 
age across groups (range was 62–65 years, P , 0.01).
In the bimatoprost, latanoprost, and BAK-free travoprost 
treatment groups, 51.3%, 37.3%, and 35.0%, respectively, 
initiated adjunctive therapy during the course of the year at 
significantly different proportions (P , 0.0001, see Table 3). 
Patients on BAK-free travoprost were able to continue with-
out adjunctive therapy longer than patients treated with other 
prostaglandins. The median number of days until the patients 
added adjunctive therapies was 83 for bimatoprost, 101 for 
latanoprost, and 113 for patients for BAK-free travoprost. 
The mean number of days to initiating adjunctive therapy 
were 221 in the BAK-free travoprost group, 140 for patients 
receiving bimatoprost, and 181 for patients receiving latano-
prost (P , 0.0001).
The types of adjunctive therapies used also appeared 
to   differ across index therapies, although comparisons are 
difficult to interpret because of the use of fixed   combination 
therapies. For example, among patients treated with 
  BAK-free travoprost and latanoprost, beta-blockers were 
the most commonly used adjunctive medication, while for 
the   bimatoprost-treated patients, a fixed combination therapy 
of beta-blocker and   carbonic anhydrase inhibitor was most 
common. However, across therapies, the rate of use of any 
beta-blocker (ie, alone or as part of a combination therapy) 
was fairly consistent, ranging from 60% to 64%, and the rate 
of use of any   carbonic   anhydrase inhibitor was only slightly 
more variable (35%–42%). Since the “other adjunctive 
therapy” category includes other fixed   combination   therapies, 
such as a combination of an α2-adrenegeric receptor agonist 
and beta-blocker, or different doses of medications, compari-
sons are not useful.
Medical costs, ie, ophthalmic visits and procedures 
(excluding surgical procedures), prostaglandin analogs, and 
adjunctive therapies, were estimated at $2557 for patients 
initiating with BAK-free travoprost, $3147 for patients initi-
ating with bimatoprost, and $2843 for patients initiating with 
latanoprost. Sensitivity analyses that explored clinical and 
cost parameters did not change the direction or magnitude of 
findings substantially. Surgical procedures were not included 
in the costs because of the low frequency and the similarity 
in rates across index prostaglandins.
Table 4 presents findings on the rate of surgical   procedures 
for glaucoma among the study population. There were too 
few patients who received BAK-free travoprost to compare 
rates for certain procedures, but rates for most procedures 
were similar across treatment groups.
Table 2 Unit costs
Resource Description/Size Cost*
initial visit CPT 92004 (comprehensive,  
new patient) plus weighted  
costs for visual field examination  
(CPT 92082), gonioscopy  
(CPT 92020), evaluation of optic 
disc (CPT 92135), optic nerve  
head photograph (CPT 92235),  
and fundus evaluation (CPT 92250)  
per Fremont et al17
$582.6120
Follow-up visit CPT 92012 (intermediate,  
established patient) and visual  
acuity examination (CPT 99173) per   
Fremont et al17
$117.6820
Prostaglandin analog 2.5 mL $81.6019
Fixed-combination  
dorzolamide 2.0%-  
timolol 0.5%
5 mL $130.8019
Brimonidine 0.1% 5 mL $62.8019
Brinzolamide 1.0% 10 mL $91.3819
Timolol 0.25% 5 mL $17.9319
Other 5 mL $75.73 
(assumption)
Note: *Costs are expressed in 2009 US$.
Participants who had
24 months of uninterrupted
use of BAK-free travoprost
N = 203 (52%)
Participants who
switched or discontinued
N = 186 (48%)
Participants using
BAK-free travoprost
N = 389
Participants who had
24 months of uninterrupted
use of latanoprost
N = 1,651 (51%)
Participants who
switched or discontinued
N = 1596 (49%)
Participants using
latanoprost
N = 3,247
Participants who had
24 months of uninterrupted
use of bimatoprost
N = 747 (54%)
Participants who
switched or discontinued
N = 635 (46%)
Participants using
bimatoprost
N = 1,382
Patients with no previous
glaucoma medications prior to
starting on a prostaglandin analog
N = 5018
Figure 1 Patient selection.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Discussion
This analysis adds to findings from previous   studies that 
explored the one-year treatment patterns of patients   initiating 
on prostaglandin analogs4,5 by providing a more com-
prehensive and longer follow-up analysis. The extended 
follow-up period (24 versus 12 months) and availability of 
procedural data provides information on long-term patterns of 
care for patients with glaucoma not available in   previous pub-
lished studies. While previous studies found rates of adjunc-
tive therapy use to range from 12% (BAK-free   travoprost6) 
to 23% (bimatoprost6) over one year, we found that this 
increased to a range of 35% (BAK-free travoprost) to 51% 
(bimatoprost) of patients requiring adjunctive therapy over 
two years. Interestingly, the median time to adding adjunc-
tive therapy was in the same range for BAK-free travoprost 
(116 days in this analysis versus 109–159 days in previous 
analyses) while the median times to initiating adjunctive 
therapy with bimatoprost or latanoprost were longer in this 
analysis than in previous analyses (for bimatoprost 83 days 
compared with 53–73 days in previous studies; for latanoprost 
101 days compared with 63–74 days in previous studies).4,5 A 
full electronic health record might provide more information 
explaining these differences, and a meta-analysis of previous 
studies suggests that there may be significant differences in 
efficacy across these medications.21
Consistent with previous studies, the average cost per 
patient over the observation period was lowest in the cohort 
with the longest duration of monotherapy. Since the differ-
ence in monotherapy rates was more than 15% (48.7% for 
bimatoprost and 65.0% for BAK-free travoprost), the addi-
tional follow-up visits for patients who switched therapies also 
had an impact on the cost differences. In fact, when the rates 
Table 4 rate of surgical procedures during observation period (number per patient)
Procedure CPT BAK-free travoprost Bimatoprost Latanoprost
Laser trabeculoplasty1 68566 0.000 0.000 0.000
Trabeculectomy, no previous surgery2 66170 0.005 0.024 0.010
Trabeculectomy, previous surgery or trauma2 66172 0.015 0.007 0.004
Aqueous shunt to reservoir2 66180 0.034 0.013 0.010
revision of aqueous shunt3 66185 0.000 0.003 0.002
iridectomy, peripheral, for glaucoma3 66625 0.000 0.000 0.000
iridectomy, sector, for glaucoma1 66630 0.000 0.000 0.000
Cyclophotocoagulation, transscleral2 66710* 0.005 0.003 0.006
Cyclophotocoagulation, endoscopic4 66711 0.000 0.007 0.001
Laser iridotomy2 66761 0.015 0.033 0.036
Laser iridoplasty1 66762 0.000 0.003 0.005
Total 0.074 0.093 0.078
Notes: *in 2006, this included 66711; 1none performed; 2not significantly different across treatment groups; 3no significant difference between bimatoprost and latanoprost; 
comparison with BAK-free travoprost could not be performed due to sample size; 4rate significantly lower for latanoprost than bimatoprost, BAK-free travoprost rate similar 
to bimatoprost. 
Abbreviations: BAK, benzalkonium chloride, CPT, Current Procedural Terminology.
Table 3 Treatment patterns and costs during observation period
Treatment pattern BAK-free travoprost Bimatoprost Latanoprost
number remaining on index therapy (n) 203 747 1651
remained on monotherapy (%)** 65.0% 48.7% 62.8%
required adjunctive therapy (%)** 35.0% 51.3% 37.3%
Median time to adding adjunctive therapy (days) 113 83 101
Mean time to adding adjunctive therapy (days); 
mean ± SD (interquartile range)**
221 ± 223 
(56–397)
140 ± 156 
(34–175)
181 ± 187 
(41–263)
Type of adjunctive therapy
 α 2-adrenergic receptor agonist (%) 19.7% 26.1% 24.6%
  Beta-blocker (%) 35.2% 24.5% 34.1%
  Carbonic anhydrase inhibitor (%) 7.0% 7.0% 5.4%
  Fixed-combination beta-blocker- carbonic anhydrase-inhibitor (%) 28.2% 35.2% 29.4%
  Other adjunctive therapy (%) 9.9% 7.0% 6.5%
  number of prescriptions of index prostaglandin 10.7 ± 6.2 13.5 ± 7.6 13.6 ± 9.5
Total costs, 24 months $2556.87 $3147.40 $2842.60
Note: **P , 0.0001 across treatment groups.
Abbreviations: BAK, benzalkonium chloride; SD, standard deviation.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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of monotherapy were equalized across cohorts in sensitivity 
analyses, the magnitude of the difference in total costs was 
halved.
Previous analyses for which only prescription claims 
data were available left open the question about whether 
low persistence was associated with the use of glaucoma 
surgical interventions. That is, were patients able to discon-
tinue therapies because of a successful glaucoma surgical 
intervention? While these data do not show the success rates 
of interventions, the analysis demonstrated very low use of 
glaucoma surgical interventions across index medications in 
the first two years after initiating treatment. Therefore, for 
those patients who are new to glaucoma therapy, surgical 
interventions would not be the reason for the high rate of 
patients stopping all glaucoma medications.
As with any claims database analysis, there are certain limi-
tations that should be acknowledged. The use of a large claims 
database offers an important strength in terms of sample size 
but shortcomings remain. For example, the patient population 
in any given database may not match the general population 
of patients with the condition in question, although in this 
analysis, the age and gender of the population reflect that of the 
general glaucoma population.22 Other characteristics, such as 
race, educational status, or self-reported health status, among 
others, are unknown. Along those lines, it is important to note 
that patients in the study database were not randomized to 
treatment. Further, various clinical or personal characteristics 
that may be associated with treatment assignment cannot be 
known from the database. Some clinical characteristics can be 
examined, eg, there is some evidence that glaucoma patients 
taking antihypertensive drugs may have different adjunctive 
therapy rates23 but we did not undertake such an analysis. The 
population of prescribers may not accurately reflect national 
patterns, which could affect   generalizability. Similarly, the 
treatment selection process may vary based on region, past 
success with the treatment, and many other factors.24,25 Most 
claims databases have little or no data on the characteristics of 
prescribers but, because the data were from a large managed 
care organization, it is likely that there is a wide distribution 
of prescribers and practices. By their nature, claims databases 
only provide information on people with some type of insur-
ance coverage, and those with coverage may be more likely 
to seek out and adhere to treatment. Finally, claims databases 
may contain coding biases or errors, although there is no 
reason to believe that these errors would be different across 
index treatments. In addition, the claims in this database were 
reviewed and adjudicated before the database was prepared 
for this analysis.
The methodology for patient selection in this study is 
also subject to certain limitations. The study attempted to 
identify only patients who were new to therapy by   requiring 
six months of glaucoma-free claims prior to the first 
  prostaglandin analog prescription. However, there is no way 
to account for product samples, which one study identified 
as being received by 20% of patients,3 and which could 
translate into patients who were already taking prostaglandin 
analogs before our study identified them. Also, based on this 
study methodology, patients with poor adherence could have 
been included, because patients in the cohort analysis were 
required to have a minimum of two glaucoma prescriptions 
filled during the 24-month follow-up period, but no attempt 
was made to assess medication possession ratio.
Conclusion
This study found that over two years, the rate of   adjunctive 
therapy use was lower and time to initiating   adjunctive therapy 
was longer with a BAK-free prostaglandin   analog   compared 
with other alternatives. The reasons for this   advantage are 
unknown. It cannot be ruled out that   differences in physicians’ 
prescribing patterns affects these findings. This difference in 
treatment patterns was not associated with glaucoma surgical 
interventions, which were at a low rate of use and similar across 
patient cohorts. Different rates of use of adjunctive therapy led 
to a substantial difference in costs over a two-year period. A 
full medical record review could help explore the reasons for 
low persistence rates and the advantages to minimizing BAK in 
the treatment of patients with primary open-angle glaucoma.
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